Citations

Mayo Clinic

Showing 10 of 108599 citations.

The Predictive Value of Risk Factors and Prognostic Scores in Hospitalized COVID-19 Patients
Brajković, Milica , Nikolić, Sofija , Branković, Marija , Sekulić, Ana , Popadić, Višeslav , Stjepanović, Mihailo , Radojevic, Aleksandra , Milić, Nataša , Tanasilovic, Srdjan, Todorović, Zoran , Zdravković, Marija , Brankovic, Marija , Popadic, Viseslav , Radojevic, Aleksandra , Todorovic, Zoran , Zdravkovic, Marija , Milic, N , Stjepanovic, Mihailo , Vukčević, Miodrag , Dukić, Marija , Markovic‐Denic, Ljiljana , Rajović, Nina

Diagnostics | August 11, 2023 | Volume: 13 | Issue: 16 | Pages: 2653

10.3390/diagnostics13162653 | PMID 37627912 Get It

Introduction: Risk stratification in patients with COVID-19 is a challenging task. Early warning scores (EWSs) are commonly used tools in the initial assessment of critical patients. However, their utility in patients with COVID-19 is still undetermined. Aim: This study aimed to discover the most valuable predictive model among existing EWSs for ICU admissions and mortality in COVID-19 patients. Materials and methods: This was a single-center cohort study that included 3608 COVID-19 patients admitted to the University Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia, between 23 June 2020, and 14 April 2021. Various demographic, laboratory, and clinical data were collected to calculate several EWSs and determine their efficacy. For all 3608 patients, five EWSs were calculated (MEWS, NEWS, NEWS2, REMS, and qSOFA). Model discrimination performance was tested using sensitivity, specificity, and positive and negative predictive values. C statistic, representing the area under the receiver operating characteristic (ROC) curve, was used for the overall assessment of the predictive model. Results: Among the evaluated prediction scores for 3068 patients with COVID-19, REMS demonstrated the highest diagnostic performance with the sensitivity, PPV, specificity, and NPV of 72.1%, 20.6%, 74.9%, and 96.8%, respectively. In the multivariate logistic regression analysis, aside from REMS, age (p < 0.001), higher CT score (p < 0.001), higher values of urea (p < 0.001), and the presence of bacterial superinfection (p < 0.001) were significant predictors of mortality. Conclusions: Among all evaluated EWSs to predict mortality and ICU admission in COVID-19 patients, the REMS score demonstrated the highest efficacy.
Artificial Intelligence-Enabled Electrocardiogram in the Detection of Patients at Risk of Atrial Secondary Mitral Regurgitation
Naser, Jwan A. , Lee, Eunjung , Michelena, Héctor I. , Lin, Grace , Pellikka, Patricia A. , Nkomo, Vuyisile T. , Noseworthy, Peter A. , Friedman, Paul A. , Attia, Zachi I. , Pislaru, Sorin V. , Sabbah, Michael S. , Noseworthy, Peter A , Nkomo, Vuyisile T , Pellikka, Patricia A , Michelena, Hector I , Attia, Zachi I , Lin, Grace , Naser, Jwan A

Circulation: Arrhythmia and Electrophysiology | August 11, 2023 | Volume: 16 | Issue: 9 | Pages: No page available

10.1161/circep.123.012033 | PMID 37565338 Get It

Development and Implementation of an Acute Kidney Injury Remote Patient Monitoring Program: Research Letter
Charkviani, Mariam , Frazee, Erin N. , Pearson, Kristina K., Amberg, Brigid M. , Amundson, Rachel H., Bell, Sarah, Cleveland, Eric J., Kohler, Christopher M., Leuenberger, Angela , Reinschmidt, Karen J. , Kattah, Andrea G. , Frazee, Erin N , Bell, Sarah J. , Daniels, Craig E, Leuenberger, Angela M, Ramirez, David A, Zoghby, Ziad , Kattah, Andrea G , Daniels, Craig , Philpot, Lindsey M. , Ramirez, David A.

Canadian Journal of Kidney Health and Disease | August 11, 2023 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/20543581231192746 | PMID 37577175 Get It

Acute kidney injury (AKI) survivors have a dynamic posthospital course which warrants close monitoring. Remote patient monitoring (RPM) could be used to improve quality and efficiency of AKI survivor care. Objective: The objective of this report was to describe the development and preliminary feasibility of an AKI RPM program launched in October 2021. Setting: Academic medical center. Patients: Patients enrolled in the AKI RPM program were those who experienced AKI during a hospitalization and underwent nephrology consultation. Measurements/Methods: At enrollment, patients were provided with home monitoring technology and underwent weekly laboratory assessments. Nurses evaluated the data daily and adhered to prespecified protocols for management and escalation of care if needed. Results: Twenty patients were enrolled in AKI RPM in the first 5 months. Median duration of program participation was 36 (31, 40) days. Eight patients (40%) experienced an unplanned readmission, or an emergency department visit, half (N = 4) of which were attributed to AKI and related circumstances. Of the 9 postgraduation survey respondents, all were satisfied with the RPM program and 89% would recommend RPM to other patients with similar health conditions. Limitations: Acute kidney injury RPM was made possible by the existing infrastructure in our integrated health system and the robust resources available in the Mayo Clinic Center for Digital Health. Such infrastructure may not be universally available which could limit scale and generalizability of such a program. Conclusions: Remote patient monitoring can offer a unique opportunity to bridge the care transition from hospital to home and increase access to quality care for the AKI survivors.
Comparative renal risk of long-term use of beta-lactams in combination with vancomycin across the continuum of care
Dolly, Lauren M. , Mara, Kristin C. , Schreier, Diana J., Virk, Abinash , Jensen, Kelsey L, Arensman Hannan, Kellie N, Mara, Kristin C , Rivera, Christina G. , Jensen, Kelsey , Hannan, Kellie N. Arensman

Therapeutic Advances in Infectious Disease | August 11, 2023 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/20499361231189589 | PMID 37576023 Get It

Background: Data are controversial regarding nephrotoxicity risk with vancomycin plus piperacillin–tazobactam (VPT) compared to vancomycin alone or in combination with other beta-lactams (BLs) in acute care use. Furthermore, data are lacking on the incidence of acute kidney injury (AKI) with long-term use of VPT including outpatient parenteral antimicrobial therapy (OPAT). Methods: This retrospective study included 826 adult patients on an intravenous vancomycin plus BL for ⩾2 weeks, including cefepime, piperacillin/tazobactam, ertapenem, or meropenem, from August 2017 to January 2022. The primary outcome was incidence of AKI. Univariate and multivariable Cox proportional hazard regression analyses were conducted to adjust for confounding variables. A secondary analysis based on the propensity score (PS)-matched cohort was performed. Results: AKI occurred in 14.4% of patients in the VPT group ( n = 15/104) compared to 5.5% in the other BL group ( n = 40/722) ( p < 0.001). Average time to AKI from start of combination therapy was 9.4 (1.7–12.0) days in the VPT group and 10.9 (5–22.7) days in the other BL group ( p = 0.20). The median duration of vancomycin and BL in the overall cohort was approximately 1 month. Beyond BL selection, patient characteristics were not associated with AKI other than the receipt of concomitant acyclovir [hazard ratio (HR) 2.48 (95% confidence interval (CI): 1.33–4.65), p = 0.004]. In the PS-matched cohort, AKI occurred in 14.4% of patients in the VPT group ( n = 15/104) and 5.3% in the other BL group ( n = 11/208) ( p = 0.006). Receipt of VPT [HR: 2.55 (1.36–4.78), p = 0.004] and acyclovir [HR: 2.38 (1.19–4.74), p = 0.014) remained significantly associated with AKI in the multivariable model. Conclusion: Clinicians should exercise caution when using VPT for >2 weeks, including in the OPAT setting, even when no renal dysfunction is observed during the initial week of combination therapy.
Position comparison of sport-related concussions in female youth soccer players
Worrall, Hannah , Podvin, Caroline , Althoff, Claire , Chung, Jane , Sugimoto, Dai , Stokes, Mathew , Radel, Luke C. , Miller, Shane M. , Cullum, C. Munro , Jones, Jacob C.

The Physician and Sportsmedicine | August 11, 2023 | Volume: 52 | Issue: 4 | Pages: 325-332

10.1080/00913847.2023.2246869 | PMID 37564006 Get It

Accuracy of the Early Diagnosis of Parkinson's Disease
Beach, Thomas G. , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Adler, C H , Zhang, Nan , Serrano, Geidy E.

Movement Disorders | August 11, 2023 | Volume: 38 | Issue: 8 | Pages: 1573-1574

10.1002/mds.29556 | PMID 37565398 Get It

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
Zarif, Talal El , Pond, Gregory R. , Zhuang, Tony , Master, Viraj A. , Nazha, Bassel , Niglio, Scot A. , Simon, Nicholas I. , Hahn, Andrew W. , Pettaway, Curtis A. , Tu, Shi‐Ming, Abdel‐Wahab, Noha , Velev, Maud , Flippot, Ronan , Maruzzo, Marco , Yang, Yuanquan , Rodriguez, Pablo Alvarez, Castellano, Daniel , Velasco, Guillermo de , Roviello, Giandomenico , Antonuzzo, Lorenzo , McKay, Rana R. , Hui, Gavin , Drakaki, Alexandra , Glover, Michael , Khaki, Ali Raza , El‐Am, Edward , Patel, Vaibhav G. , Piedra, A. , Gernone, Angela , Davis, Nancy B. , Matthews, Harrison, Giudice, Giulia Claire , Farolfi, Alberto , Milowsky, Matthew I. , Appleman, Leonard J. , Freeman, Dory , Sonpavde, Guru , El Zarif, Talal , Nazha, Bassel , Hahn, Andrew W , Antonuzzo, Lorenzo , Khaki, Ali Raza , El-Am, Edward , Appleman, Leonard , Choueiri, Toni K , Spiess, Philippe E , Necchi, Andrea , Sonpavde, Guru , Pond, Gregory Russell , Nassar, Amin H. , Tu, Shi‐Ming , Buti, Sebastiano , Mittra, Arjun , Gheeya, Jinesh , Vincenzi, Bruno , Cortellini, Alessio , Drakaki, Alexandra , Adra, Nabil , Mouhieddine, Tarek H. , Harrison, Michael R. , Kanesvaran, Ravindran , Barata, Pedro C. , Lee, Jae‐Lyun , Stahlfeld, Charlotte N. , Kim, Joseph W. , Choueiri, Toni K. , Spiess, Philippe E. , Necchi, Andrea , Apolo, Andrea B

JNCI: Journal of the National Cancer Institute | August 11, 2023 | Volume: 115 | Issue: 12 | Pages: 1605-1615

10.1093/jnci/djad155 | PMID 37563779 Get It

Abstract Background Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors. Methods This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma receiving immune checkpoint inhibitors between 2015 and 2022 across 24 centers in the United States, Europe, and Asia. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. Objective response rates were determined per Response Evaluation Criteria in Solid Tumours 1.1 criteria. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events, version 5.0. Two-sided statistical tests were used for comparisons. Results Among 92 patients, 8 (8.7%) were Asian, 6 (6.5%) were Black, and 24 (29%) were Hispanic and/or Latinx. Median (interquartile range) age was 62 (53-70) years. In all, 83 (90%) had metastatic penile squamous cell carcinoma, and 74 (80%) had received at least second-line treatment. Most patients received pembrolizumab monotherapy (n = 26 [28%]), combination nivolumab-ipilimumab with or without multitargeted tyrosine kinase inhibitors (n = 23 [25%]), or nivolumab (n = 16 [17%]) or cemiplimab (n = 15 [16%]) monotherapies. Median overall and progression-free survival were 9.8 months (95% confidence interval = 7.7 to 12.8 months) and 3.2 months (95% confidence interval = 2.5 to 4.2 months), respectively. The objective response rate was 13% (n = 11/85) in the overall cohort and 35% (n = 7/20) in patients with lymph node–only metastases. Visceral metastases, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or higher, and a higher neutrophil/lymphocyte ratio were associated with worse overall survival. Treatment-related adverse events occurred in 27 (29%) patients, and 9.8% (n = 9) of the events were grade 3 or higher. Conclusions Immune checkpoint inhibitors are active in a subset of patients with penile squamous cell carcinoma. Future translational studies are warranted to identify patients more likely to derive clinical benefit from immune checkpoint inhibitors.
Gastrointestinal: Progressive dyspnea after motor vehicle accident due to traumatic diaphragmatic rupture with herniation of multiple abdominal organs
Kamboj, AK, Shen, KR, Tapias, LF, Kamboj, A K

Journal of Gastroenterology and Hepatology | August 11, 2023 | Volume: 39 | Issue: 1 | Pages: 34-34

10.1111/jgh.16323 | PMID 37563774 Get It

Outcomes with transplanting kidneys offered through expedited allocation
Ohara, Stephanie , Punukollu, Rachana , Wagler, Josiah , Ruch, Brianna , Kumm, Kayla , Budhiraja, Pooja , Me, Hay Me , Mathur, Amit K. , Reddy, Kunam S. , Khamash, Hasan , Heilman, Raymond L. , Jadlowiec, Caroline , Ohara, Stephanie Y , Punukollu, Rachana , Budhiraja, Pooja , Mathur, Amit , Heilman, Raymond , Jadlowiec, Caroline C.

Clinical Transplantation | August 11, 2023 | Volume: 37 | Issue: 11 | Pages: No page available

10.1111/ctr.15094 | PMID 37563488 Get It

AbstractIntroductionExpedited out‐of‐sequence deceased donor kidney allocation is a strategy to avoid discards after early placement attempts have been unsuccessful. Our study aimed to assess outcomes and characteristics of these transplanted kidneys.MethodsKDPI matching was performed between expedited allocation (EA) and standard allocation (SA) deceased donor kidney transplants performed at our center.ResultsBetween 2018 and 2021, there were 225 EA offers, and 189 (84%) were transplanted. EA recipients were older (p = .007) and had shorter dialysis vintage (p < .0001). EA kidneys were likely to be nationally allocated (p < .001), have AKI (p < .0001) and longer CIT (p < .0001). There were no differences in EA and SA time‐zero kidney biopsies (ci, p = .07; ct, p = .89; cv, p = .95; ah, p = .79). EA kidneys had more DGF (p = .0006), but there were no differences in DGF duration (p = .83), hospital length of stay (p = .43), 1‐ and 2‐year eGFR (p = .16, p = .99), patient (p = .34), or death‐censored graft (p = .66) survival.ConclusionDuring this study period, our center transplanted 189 kidneys through EA following local‐regional declines. These kidneys often came from AKI donors and had more DGF but had similar outcomes to KDPI‐matched SA kidneys. Although it has been suggested that EA has the potential to worsen transplant disparities, transplant center level decisions on organ acceptance contribute to these variations.
The use of complementary and alternative medicine for the treatment of gastrointestinal symptoms in Long COVID: a systematic review
Gawey, Brent J. , Yang, Juan , Bauer, Brent A. , Song, Joanne, Gawey, Brent , Bauer, Brent, Wang, Xiao‐Jing

Therapeutic Advances in Chronic Disease | August 11, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/20406223231190548 | PMID 37577106 Get It

Background: Most people with coronavirus disease 2019 (COVID-19) experience resolution of symptoms within days to weeks following initial infection. In a subset of individuals, symptoms persist longer than 4 weeks, known as ‘Long COVID’. Many gastrointestinal (GI) symptoms persist as part of this syndrome; yet, an approach to treatment remains unclear. Prior studies have demonstrated the efficacy of complementary and alternative medicine (CAM) for the treatment of acute COVID-19 infections, but little data exist regarding the potential use of CAM in the treatment of Long COVID. Objectives: Identify CAM approaches useful in treating the GI symptoms of Long COVID. Design: A systematic review of studies reporting on the use of CAM for the treatment of GI symptoms of Long COVID was performed. Data Sources and Methods: Five electronic databases were searched from January 2019 to November 2022. Studies describing the use of CAM to treat GI symptoms of Long COVID were included and assessed by two independent reviewers. Studies not reporting on GI symptoms or using CAM were excluded. Studies chosen for final review underwent quality and bias assessment using predetermined criteria. The extracted data were synthesized utilizing a framework derived from the National Center of Complementary and Integrative Health categories. Results: The initial search yielded 396 articles. After applying the eligibility criteria, a total of four studies (three case reports and one case series) were included for final review. Two studies used nutritional supplements and two studies used traditional Chinese medicine. Reductions in nausea, loss of appetite, diarrhea, acid reflux, epigastric pain, and bloating were reported. Conclusion: This is the first systematic review to explore the role of CAM in treating GI manifestations of Long COVID. The review identified four studies, all reporting reductions in the GI symptoms of Long COVID. Despite the positive studies included in this review, the overall search yielded few results, all of which were non-experimental. As the post-infectious sequelae of COVID-19 become better recognized in the wake of the pandemic, higher-quality clinical studies are needed.